trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['solid tumor', 'enhertu', 'daiichi']
 exciting news from asco 2023! daiichi sankyo's enhertu shows a confirmed objective response rate (orr) of 37.1% in previously treated patients with her2 expressing advanced solid tumors. #asco2023 #solidtumors #precisionmedicine in the ongoing d 
Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines